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a  b  s  t  r  a  c  t
In two  work  packages  of  the MARK-AGE  project,  37 immunological  and physiological  biomarkers  were
measured  in  3637  serum,  plasma  or blood  samples  in ﬁve  batches  during  a  period  of 4 years.
The quality  of the  serum  and  plasma  samples  was  very  good  as  judged  by  the  low  number  of biomarker
measurements  (only  0.2%)  that were rejected  because  of  a  high  hemolysis,  icteria  or lipemia  of  the
samples.
Using quality  control samples,  day-to-day  and batch  variations  were  determined.  The  mean  inter-assay
variation  of  the  ﬁve  batches  were  all below  8%, with  an  average  inter-assay  coefﬁcient  of variation  of  all
biomarkers  of  4.0%.  Also  the precision  of  the  measurements  was  very  good,  because  all  measurements
were  between  90%  and  115%  of  the  deﬁned  target  values.A possible  mix-up  of  samples  was  determined  by  comparison  of  the  extreme  testosterone  levels  of
men  and  women.  It was concluded  that 3%  of the sample  identiﬁcation  could  be  mixed-up.
Considering  the complex  procedure  from  collection  to  analysis,  including  preparation,  handling,  ship-
ment  and  storage,  of the  samples  in  the  MARK-AGE  project,  both  the  quality  of the samples  and  the
nts  aquality  of the  measureme
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1. Introduction
MARK-AGE is a large-scale integrated project supported by the
European Commission. The major aim of this project is to conduct
a population study in order to identify a set of biomarkers of ageing
which, as a combination of parameters with appropriate weighting,
would measure biological age better than any marker in isolation.
A total of 37 immunological and physiological biomarkers were
measured in 3637 serum, plasma or blood samples at the Cen-
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
E. Jansen et al. / Mechanisms of Ageing and Development 151 (2015) 54–59 55
Fig.1. Mean inter-assay CVs (expressed as %) of 36 biomarkers measured in the different series of the MARK-AGE project.
56 E. Jansen et al. / Mechanisms of Ageing and Development 151 (2015) 54–59
Table  1
List of all physiological and immunological biomarkers, measured by the National Institute for Public Health and the Environment in Bilthoven, the Netherlands and the
material and method of analysis.
Biomarker Abbreviation Matrix Method of analysis Company of assay Assay product nr
25hydroxy-vitamin D 25OHVitD EDTA EIA IDS AC57F1
2-macroglobulin AMG  Serum Autoanal Dialab A00505
Alanine aminotransferase ALT EDTA Autoanal Beckman 476826
Albumin ALB EDTA Autoanal Beckman 442765
IgG  ab against 8 nuclear antigens ANA-8 Serum EIA Dialab R99419
IgG  ab against cytomegalovirus CMV-ab Serum EIA DRG EIA-3468
Thyroglobulin autoantibodies TG-ab EDTA Immunoanal Beckman A32898
Ceruloplasmin CER Serum Autoanal Dialab A00531
Cholesterol CHOL Serum Autoanal Beckman 467825
Creatinine CREA EDTA Autoanal Beckman 442760
Dehydroepiandrosterone sulphate DHEA-S EDTA Immunoanal Beckman A10826
Total iron Fe Serum Autoanal Beckman 467910
Ferritin FER Serum Immunoanal Beckman 33020
Fibrinogen FIB EDTA Autoanal Dialab A00517
Free  fatty acids FFA Serum Autoanal Wako NEFA-HR
ϒ-Glutamyl transferase GGT Serum Autoanal Beckman 476846
Glucose GLU Serum Autoanal Beckman 442640
Hemoglobin Hb Blood Autoanal Beckman A17836
Glycated hemoglobin HbA1c Blood Autoanal Beckman A17836
Homocysteine HCy EDTA Autoanal Dialab 908520
High-density lipoprotein cholesterol HDL-C Serum Autoanal Beckman 650207
High-sensitive C-reactive protein HS-CRP Li-Hep Autoanal Beckman 378020
Immunoglobulin A IgA Serum Autoanal Beckman 467920
Immunoglobulin E IgE Serum Immunoanal Beckman 35000
Immunoglobulin G IgG Serum Autoanal Beckman 467925
Immunoglobulin M IgM Serum Autoanal Beckman 467930
Insulin INS EDTA immunoanal Beckman 33410
Low-density lipoprotein cholesterol LDL-C Serum Autoanal Beckman 969706
Prostate speciﬁc antigen PSA Serum Immunoanal Beckman 37200
Serotonin SER Serum EIA Biosource 10-0900
Testosterone TEST Serum immunoanal Beckman 33560
Total protein of serum s-TP Serum Autoanal Beckman 442740
Total protein of plasma p-TP EDTA Autoanal Beckman 442740
Transferrin TFN Serum Autoanal Beckman 467942
Triglycerides TG Serum Autoanal Beckman 445850
Urea UREA EDTA Autoanal Beckman 442820
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bbreviations:  EDTA = EDTA-plasma; Li–hep = lithium–heparin plasma; autoanal = a
er for Health Protection of the Dutch National Institute for Public
ealth and the Environment within Work package 4: “Immunolog-
cal markers” and Work package 5: “Clinical chemistry, hormones
nd markers of metabolism”.
In this paper we present quality control data, day-to-day and
atch variations and a possible number of sample exchanges for
he whole 4-year period.
. Materials and methods
In the MARK-AGE project in total 3637 samples were distributed
mongst the various laboratories from the coordination centre at
he University of Hohenheim. In the Center for Health Protection of
he Dutch National Institute for Public Health and the Environment
n Bilthoven, 37 biomarkers have been measured. The biomarkers
ere measured in serum, EDTA-plasma, citrate plasma and ery-
hrocytes in 5 batches (1444, 775, 685, 354 and 379 samples) over
 4-year period.
For each biomarker, two reference samples were included in
he daily routine. Each day about 100 samples were measured. In
ddition, each sample was checked for hemolytic (H), icteric (I) and
ipemic (L) disturbances by measuring the H-, I- and L-index on the
linical auto-analyzer (LX20-Pro, Beckman–Coulter, Woerden, The
etherlands).
All assays measured on the LX20 autoanalyzer were obtained
rom Beckman–Coulter, except HCy and AMG  (Dialab, Neudorf,
ustria), FFA (Wako Diagnostics, Neuss, Germany). Most of the
ssays on the LX20 were enzymatic assay with a colorimetric end-Autoanal Beckman 442785
lyzer; immunoanal = immunoanalyzer; EIA = enzyme immunoassay.
point. The assays for AMG, CER, FIB, HbA1c, HDL-C, LDL-C, HS-CRP,
IgA, IgG, IgM and transferrin were performed using turbidimet-
ric assays (immunoprecipitation). An extensive description of the
LX20 autoanlyzer including the different assays was  describerd by
Mikolaenko et al., (2000).
Seven biomarkers have been measured with an immuno-
analyzer (Access-2, Beckman–Coulter, Woerden, The Netherlands).
These 7 biomarkers were dedicated assays on the Access-2
and obtained from Beckman–Coulter. The Access-2 system is an
automated immunoanalyzer based of the principle of chemilu-
minescence detection using acridinium esters. The assays are
performed in a homogenous format without the necessity of
pretreatment of the samples. An extensive description of the
immunoanalyzer and the dedicated assays have been described
by Patterson et al., (1994). Four biomarkers have been mea-
sured with enzyme immunoassays (EIA): 25OHVitD (OCTEIA,
AC57F1, IDS, Boldon, UK), SER (KAPL10-0900, Biosource, Niv-
elles, Belgium), CMV-ab (EIA-3468, DRG Diagnostics, Marburg,
Germany), ANA-8 (ANA Screen 8 IgG, R99419, Dialab, Neudorf,
Austria). Technical information about the biomarkers can be found
in Table 1.
3. ResultsIn each serum and plasma sample, a ﬁrst quality control check
was done by the determination of the extent of hemolysis, high
levels of bilirubin or lipids, expressed as hemolytic, icteric and
lipemic index (H-, I- and L-index), respectively, measured by an
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utomatic procedure on the clinical auto-analyzer. Each of these
hree indices is expressed in arbitrary units from 0 to 10. For most
f the biomarkers, threshold values are known for each of the three
ndices (Vermeer et al., 2007). If one of the three indices of the sam-
le is higher than the established threshold values for a particular
iomarker, the determined value of the biomarker is probable to
eviate from a normal sample condition and therefore the respec-
ive biomarker value should be discarded.For EDTA–plasma the three indices were determined in 3637
amples and compared with the threshold values that were known
or 12 biomarkers. The result of this quality check was  that of 43,644
iomarker values, only 49 (0.11%) used should be excluded for anal-
ig. 2. Histogram of the testosterone concentrations in all men (upper graph) and wom
ave  been indicated with white bars.d Development 151 (2015) 54–59 57
ysis (Table 2). For the serum samples, the threshold values of the H-,
I-, and L-index were known for 20 biomarkers. In this case, from the
72,740 determinations, 171 (0.24%) should be excluded (Table 3).
Another interesting observation was done from a comparison
between the H-, I- and L-indices in serum and EDTA plasma of
the same individuals. It appeared that the correlation between the
H-indices of serum and EDTA-plasma is rather low (0.11), whereas
the correlation of the I- and L-indices between serum and plasma
is 0.83 and 0.74, respectively (results not shown). The explana-
tion is that icteria and lipemia are an inherent property present
in the blood of the individual, whereas hemolysis is caused by the
preparation of serum and plasma.
en  (lower graph). The participants that have extreme testosterone concentrations
58 E. Jansen et al. / Mechanisms of Ageing an
Table  2
The threshold values of the H-, I- and L-indices for the biomarkers that have been
measured in serum samples and the corresponding number of data that have been
excluded from the database.
Serum H-index I-index L-index Excluded
s-TP 10 10 3 22
GLU 7 7 9 9
Fe  2 10 10 36
TRF  10 10 10 5
CER  10 10 10 5
GGT 5 10 10 8
CHOL 10 10 10 6
TG  10 3 X 7
HDL-C 10 10 10 5
LDL-C 9 10 10 5
FFA  5 10 10 8
IgG  10 10 10 5
IgA  10 10 10 5
IgM  10 10 6 9
FER 7 5 10 7
IgE  10 8 10 6
PSA 10 10 10 5
TEST 10 8 10 6
AMG  4 8 10 7
ANA-8 10 10 10 5
o
s
n
t
g
m
a
o
c
r
ﬁ
e
m
t
O
a
m
s
T
T
m
e
i
bTotal 171
0.21%
Samples with a high H-index did not correlate to age or gender
f the individuals. We  observed however that most of the hemolytic
amples originate from one center and that two centers had almost
o hemolytic serum samples.
For 26 of the 33 biomarkers measured with the auto-analyzer or
he immuno-analyzer, the reference samples had well-deﬁned tar-
et values. From the 5 series of measurements 80% of the biomarker
easurements were between 95% and 105% of the target values and
ll measurements were between 90% and 115% of the target values.
In all measuring sessions (usually 100 samples per day), at least
ne quality control sample was included. In Fig. 1 the inter-assay
oefﬁcients of variation (CVs) of one quality control sample (with
eference values in the normal physiological range) for each of the
ve series of measurements have been plotted. The CVs have been
xpressed as percentage of the standard deviation divided by the
ean value). The assay for ANA-8 was only semi-quantitative and
herefore no quantitative data of the quality control is available.
f the remaining 36 biomarkers and 180 series of measurements,
lmost all CVs were below 10%, with the exception of only ﬁve
easurements. The average CVs, being the means of the ﬁve mea-
urement series were all below 7–8%. The average inter-assay CV
able 3
he threshold values of the H-, I- and L-indices for the biomarkers that have been
easured in EDTA-plasma and the corresponding number of data that have been
xcluded from the database. The “x” in the table for TG means that the Lipemic index
n  fact is a reﬂection of the TG concentration in the sample, so no index number can
e  given.
EDTA-pl H-index I-index L-index Excluded
p-TP 10 10 3 24
ALB  10 10 10 2
UREA 10 10 10 2
CREA 10 10 10 2
ALT 2 10 9 2
FIB  10 10 10 2
DHEAS 10 10 10 2
INS  10 8 10 2
Tg-ab 10 10 10 2
UA  3 5 10 5
Hcy  10 10 10 2
25OHVifD 10 10 10 2
Total 49
0.11%d Development 151 (2015) 54–59
of all biomarkers was about 4%, whereas the clinical auto-analyzer
showed lower CVs than the immuno-analyzer and the ELISAs.
Upon completion of the measurements, gender information
was released for 2871 analysed samples, allowing the analysis
of testosterone concentration ranges for both men and women.
The normal range for testosterone in women and men  does not
overlap, being 0.06–0.86 ng/mL and 2.69–10.70 ng/mL for women
and men, respectively (Kratz et al., 2004). In Fig. 2 histograms
are shown of both the testosterone concentrations of men  (upper
graph) and women  (lower graph). We  noticed that 44 samples
from female participants were in a concentration range that is
characteristic for men  (white bars), while an identical number
of male samples, i.e. 44, had concentrations typically found in
women (white bars). Furthermore it is observed that 18 of 19
women (94%) with PSA > 1 ng/ml are among the 44 women with
most extreme testosterone concentrations. Together, these results
suggest that 88 samples were exchanged between genders, being
3%.
4. Conclusions
In the recruiter centers of the MARK-AGE project, the sam-
pling was performed according a very strict protocol (see
Moreno–Villanueva, Capri et al., this issue). As a result, the qual-
ity of the serum and plasma samples was very good. This was
judged by the three indices that were determined on the clini-
cal auto-analyzer. Both the hemolytic, icteric and lipemic index
show in general very low levels, indicating that only a small part
of the biomarkers could not be used for the ﬁnal analysis. From the
in total 116,384 biomarkers measured, only 130 (0.2%) cannot be
used because of a too high index. This percentage is comparable
with the ﬁnding of another European study on aging (see Boffetta
et al., 2014). By correlation analysis it appeared that especially the
hemolytic index determines the quality of the sample preparation
and not the icteric or lipemic index.
The quality control of the analyses was performed by including
control samples at the beginning and end of each analysis session.
The average inter-assay variation of all biomarkers was 4.0%. As is
shown in Fig. 1, the CVs of the immunochemical methods (EIA and
immunoanalyzer) are somewhat higher than the CVs of the colori-
metric assays of the autoanalyzer, because of the more complicated
assays of the immunochemical methods.
Sample exchanges or database errors are difﬁcult to avoid in
complex large-scale projects. Sample or data exchange could have
occurred at several stages, including recruiting, storage and rela-
beling of samples, samples analysis including reporting and data
storage, all done at different sites (see Bürkle et al.; Moreno-
Villanueva, Capri et al.; Capri, Moreno-Villanueva et al.; Baur et al.,
this issue). One possible check of sample mix-up is the correla-
tion between the participant’s gender and the testosterone levels.
An equal number of designated male and female samples showed
testosterone levels in the range of the opposite gender, with almost
half of the designated samples from females having the highest
PSA values measured in this group. Possibly, these samples (3%
of total) got exchanged anywhere in the chain from sample col-
lection to data analysis. As potential sample exchanges within
sexes go unnoticed in this analysis bases on sex differences, the
estimated exchange rate for all sample sets may  be twice as
high.
In the MARK-AGE project, both the quality of the serum
and plasma samples and the quality of the biomarkers
measurements are excellent, considering the complicated proce-
dures in this large-scale project. The quality includes preparation,
handling, shipments, (re)numbering, storage conditions, quality
control procedures and measurements of the blood samples.
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